GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib

The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.

Related Keywords

,Vitalii Vodolazskyi ,Genzada Pharmaceuticals United States Inc ,Impact Journals ,Study Evaluating ,Patients With Advanced Solid Tumors ,Combination With Capecitabine ,Genzada Pharmaceuticals United States ,